Skip to main content
. 2021 Jun 26;1(2):100034. doi: 10.1016/j.xops.2021.100034

Figure 4.

Figure 4

Retinal fluid volume-time curves for participant 2's left eye. A, Intraretinal fluid (IRF) and subretinal fluid (SRF) volume-time curves from Notal OCT Analyzer segmentation of daily home OCT self-images. The eye received intravitreal anti–vascular endothelial growth factor injections of aflibercept 7 weeks before the beginning of the study period and on day 10 of the study period. No SRF was detected during the first week, followed by the appearance of SRF that increased slowly in quantity over 2 days, from 0 to 3 nl, then increased rapidly over 1 day to 48 nl. After the injection, the SRF volume continued to increase for 1 day (to 137 nl) before leveling off and declining gradually to complete resolution over the ensuing 7 days. Over the next 11 days and until the end of the study period, SRF remained absent. No IRF was identified throughout the study period. B, Representative example of the cumulative SRF load metric represented by area under the receiver operating characteristic curve (AUC). The AUC values (in nanoliter-days) are shown for different phases of the peri-injection period: 28.4 nl-days before the injection and 504.9 nl-days after the injection, with a total AUC of 533.3 nl-days during the 12-day period. Cumulative fluid thickness map during the same period, illustrating spatially the macula’s fluid exposure in nanoliter-days over 12 days (with Early Treatment Diabetic Retinopathy Study grid overlaid).